These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34940846)

  • 41. [Theranostics and hybrid imaging for somatostatin receptor-expressing tumors].
    Werner RA; Bengel FM; Derlin T
    Radiologe; 2020 May; 60(5):413-420. PubMed ID: 32052116
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Analysis of somatostatin receptor 2A immunohistochemistry, RT-qPCR, and in vivo PET/CT data in patients with pancreatic neuroendocrine neoplasm.
    Kaemmerer D; Wirtz RM; Fischer EK; Hommann M; Sänger J; Prasad V; Specht E; Baum RP; Schulz S; Lupp A
    Pancreas; 2015 May; 44(4):648-54. PubMed ID: 25872131
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The diagnostic role of 68Ga-DOTATATE PET/CT in the detection of neuroendocrine tumours.
    Łapińska G; Bryszewska M; Fijołek-Warszewska A; Kozłowicz-Gudzińska I; Ochman P; Sackiewicz-Słaby A
    Nucl Med Rev Cent East Eur; 2011; 14(1):16-20. PubMed ID: 21751167
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B; Asopa R; Basu S
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nuclear Imaging of Neuroendocrine Tumors.
    Pollard J; McNeely P; Menda Y
    Surg Oncol Clin N Am; 2020 Apr; 29(2):209-221. PubMed ID: 32151356
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quarter Century PET/Computed Tomography Transformation of Oncology: Neuroendocrine Tumors.
    Marcus C; Muzahir S; Subramaniam RM
    PET Clin; 2024 Apr; 19(2):187-196. PubMed ID: 38160070
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular and Anatomic Imaging of Neuroendocrine Tumors.
    Szidonya L; Park EA; Kwak JJ; Mallak N
    Surg Oncol Clin N Am; 2022 Oct; 31(4):649-671. PubMed ID: 36243499
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Head-to-Head Comparison of
    Zhu W; Cheng Y; Wang X; Yao S; Bai C; Zhao H; Jia R; Xu J; Huo L
    J Nucl Med; 2020 Jun; 61(6):897-903. PubMed ID: 31676731
    [No Abstract]   [Full Text] [Related]  

  • 49. Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT/SPECT/CT Versus 68Ga-DOTATATE PET/CT Upon Clinical Management.
    Kunikowska J; Lewington V; Krolicki L
    Clin Nucl Med; 2017 Dec; 42(12):905-911. PubMed ID: 29076910
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reply to: the utility of gallium-68 PET/CT in MEN1 related parathyroid disease.
    Kostiainen I; Schildt J; Parviainen H; Ryhänen EM; Schalin-Jäntti C
    Eur J Endocrinol; 2024 Jul; 191(1):L4-L5. PubMed ID: 38828659
    [No Abstract]   [Full Text] [Related]  

  • 51. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of full-dose contrast-enhanced CT for extrahepatic staging using Gallium-68-DOTATATE PET/CT in patients with neuroendocrine tumors.
    Apitzsch J; Verburg FA; Mottaghy F; Heinzel A
    Diagn Interv Radiol; 2021 Jul; 27(4):573-579. PubMed ID: 34313245
    [TBL] [Abstract][Full Text] [Related]  

  • 53.
    Gauthé M; Dierick-Gallet A; Delbot T; Bricaire L; Bertherat J; North MO; Cochand-Priollet B; Bouchard P; Talbot JN; Groussin L; Gaujoux S
    World J Surg; 2020 Nov; 44(11):3761-3769. PubMed ID: 32681321
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis.
    Treglia G; Castaldi P; Rindi G; Giordano A; Rufini V
    Endocrine; 2012 Aug; 42(1):80-7. PubMed ID: 22350660
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients.
    Grawe F; Ebner R; Geyer T; Beyer L; Winkelmann M; Sheikh GT; Eschbach R; Schmid-Tannwald C; Cyran CC; Ricke J; Bartenstein P; Heimer MM; Faggioni L; Spitzweg C; Fabritius MP; Auernhammer CJ; Ruebenthaler J
    Eur Radiol; 2023 May; 33(5):3416-3424. PubMed ID: 36964768
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multiple endocrine neoplasia type 1 syndrome: single centre experience from western India.
    Goroshi M; Bandgar T; Lila AR; Jadhav SS; Khare S; Shrikhande SV; Uchino S; Dalvi AN; Shah NS
    Fam Cancer; 2016 Oct; 15(4):617-24. PubMed ID: 26905068
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Somatostatin Receptor-Directed PET/CT for Therapeutic Decision-Making and Disease Control in Patients Affected With Small Cell Lung Cancer.
    Serfling SE; Hartrampf PE; Zhi Y; Higuchi T; Kosmala A; Serfling J; Schirbel A; Hörning A; Buck AK; Weich A; Werner RA
    Clin Nucl Med; 2023 Apr; 48(4):309-314. PubMed ID: 36754127
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Prospective Observational Study to Evaluate the Effects of Long-Acting Somatostatin Analogs on
    Gålne A; Almquist H; Almquist M; Hindorf C; Ohlsson T; Nordenström E; Sundlöv A; Trägårdh E
    J Nucl Med; 2019 Dec; 60(12):1717-1723. PubMed ID: 31000584
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of positron emission tomography in thyroid and neuroendocrine tumors.
    Treglia G; Kroiss AS; Piccardo A; Lococo F; Santhanam P; Imperiale A
    Minerva Endocrinol; 2018 Sep; 43(3):341-355. PubMed ID: 28949122
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PET/TC imaging with somatostatin analogues for assessment of neuroendocrine tumors, initial experience.
    Suárez-Piñera M; Visa Turno L; Ilzarbe L; Zugazaga A; Poves I; Mestre-Fusco A; Iglesias M
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(6):382-385. PubMed ID: 30826325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.